Incamix 250mg HDPHARMA treat acute and chronic liver diseases (10 blisters x 10 tablets)

Dosage form Box of 10 blisters x 10 tablets
Specifications L-Ornithine-L-ASPARTATE

Ingredient

Composition information	Content
L-Ornithine-L-ASPARTATE	250mg

Uses

indications

Incamix 250 mg drug is indicated in the following cases:

Hyperactive hyperglycemia related to acute and chronic liver pathology: cirrhosis, fatty liver, viral hepatitis, drug -caused hepatitis, chemicals, alcohol ...

belongs to the liver protection drug group. The mechanism of action of the drug is caused by 2 amino acids, the composition of the active ingredient involved in the urea round. In this way, the drug has the effect of promoting the detoxification process in the liver and increases the process of excreting ammonia neurotoxic substances. Aspartat and ornithin are the substrates for glutamate synthesis in damaged liver cells.

The inverse of amino, including the transportation of amino groups from most amino acids to A - Ketoglutarate, resulting in glutamate and glutamine, a non -toxic compound. This is the main substance formed in central nervous system cells and muscle cells. Introphy -glutamine is a substance that regulates the synthesis of protein and when the amount of glutamine increases, the protein synthesis will be increased.

Aspartat is involved in citric acid ring and catalyzes the above reactions that occur easily to protect other amino acids and separated amino acids. The amino glutamate group is involved in the synthesis of carbamoylphosphate thanks to carbamylphosphate synthase. The transfer of carbamoyl groups to ornithin in the urea led to the formation of citrullin and then urea. In the Glutamate - Glutamine system that can accumulate 1/4 of ammonia content created during metabolism.

The above description reactions occur in the presence of Ornithine Carbamoyltransferase. Ornithin is an active substance of carbamoyl phosphate synthase and carbamoyltransferase. Aspartat is involved in the synthesis of pyrimidine to help regenerate nucleic acid in damaged liver cells. Thanks to this main mechanism of activity, Ornithin Aspartat is mainly used in the treatment of liver failure with the brain complications due to increased blood ammonia concentration.

Dynamic pharmacokinetics

in the body of the drug is separated into 2 amino acids. Information about pharmacokinetics of Ornithin and Aspartat has not been fully published.

Ornithin's half -life is 0.4 hours.

Before taking Incamix 250mg HDPHARMA treat acute and chronic liver diseases (10 blisters x 10 tablets)

How to use

oral medication.

Dosage

Take 3 times a day, 1-2 capsules each time, take after meals. Take drugs for 1 - 2 weeks.

Maintenance dose: Take 2 times a day, 1 capsule, take after meals. Using the drug at least 4 - 5 weeks. Treatment time depends on the condition of the disease.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose?

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Incamix 250 mg, you may experience unwanted effects (ADR).

Rare, ADR

Digestive: Nausea, vomiting, no need to stop treatment.

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Incamix 250 mg contraindicated in the following cases:

Hypersensitivity to any ingredients of the drug.

Patients with severe renal failure.

Be cautious when using

Caution when taking drugs for pregnant and lactating women.

The ability to drive and operate machinery

The drug does not affect people when driving or operating machinery.

Women during pregnancy and nursing mothers

No report on safety when using L - Ornithin L - Aspartat for pregnant and lactating women. Only use this medication for pregnant and lactating women in case of necessity.

Interactive drug

There is no report on the interaction of the drug with other drugs.

Storage

Leave in a dry place, the temperature does not exceed 30 ° C, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.